Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias

Pediatric Blood and Cancer

Volumn 50, Issue 4, 2008, Pages 822-825

  Rao, Aarati ^a   Kelly, Michael ^b,e   Musselman, Mark ^c   Ramadas, Jagadeesh ^d   Wilson, David ^a   Grossman, William ^a,e   Shenoy, Shalini ^a,f  

^a ST LOUIS CHILDREN S HOSPITAL   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^d GEISINGER MEDICAL CENTER   (United States)

^e CHILDREN S HOSPITAL OF WISCONSIN   (United States)

^f Box 8116   (United States)

Author keywords

Autoimmune hemolytic anemia; Immune thrombocytopenia; Rituximab

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHYLPREDNISOLONE; RITUXIMAB; TETANUS ANTIBODY; TETANUS TOXOID;

ADOLESCENT; ADULT; ANAPHYLAXIS; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; B LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOPENIA; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HEMOLYTIC ANEMIA; HUMAN; IMMUNOGLOBULIN DEFICIENCY; INFECTION; LYMPHOCYTE DEPLETION; MALE; MONOSOMY 7; MULTICENTER STUDY; MYELODYSPLASIA; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; REMISSION; RETREATMENT; THROMBOCYTOPENIA;

EID: 40449106057     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21264     Document Type: Article

References (20)

1. 1 Bussel J. Fc receptor blockade and immune thrombocytopenic purpura. Semin Hematol 2000 ; 37: 261–266.
2. 2 Dan K, Gomi S, Kuramoto A, et al. A multicenter prospective study on the treatment of chronic idiopathic thrombocytopenic purpura. Int J Hematol 1992 ; 55: 287–292.
3. 3 Beck C, Nathan P, Parkin P, et al. Corticosteroids versus intravenous immunoglobulins for acute idiopathic immune thrombocytopenic purpura: A systematic review and metaanalysis of randomized controlled trials. J Pediatr 2005 ; 147: 521–527.
4. 4 Sandler S, Tutuncuoglu S. Immune thrombocytopenic purpura—Current management practices. Expert Opin Pharmacother 2004 ; 5: 2515–2527.
5. 5 Vianelli N, Galli M, deVivo A, et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: Long‐term results of 402 cases. Haematologica 2005 ; 90: 72–77.
6. 6 Willis F, Marsh J, Bevan D, et al. The effect of treatment with Campath‐1H in patients with autoimmune cytopenias. Br J Haematol 2001 ; 114: 891–898.
7. 7 Pinganaud K, Lambotte O, Dreyfus M, et al. Efficacy of mycophenolate mofetil in adult refractory autoimmune cytopenias: A single center preliminary study. Eur J Haematol 2005 ; 75: 60–64.
8. 8 Wang J, Wiley J, Luddy R, et al. Chronic immune thrombocytopenic purpura in children: Assessment of rituximab treatment. J Pediatr 2005 ; 146: 217–221.
9. 9 Zecca M, Nobili B, Ramnghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 2003 ; 101: 3857–3861.
10. 10 Saleh M, Gutheil J, Moore M, et al. A pilot study of the anti‐CD20 monoclonal antibody rituximab in patients with refractory autoimmune thrombocytopenia. Semin Oncol 2000 ; 27: 99–103.
11. 11 Cooper N, Stasi R, Cunningham‐Rundles S, et al. The efficacy and safety of B cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004 ; 125: 232–239.
12. 12 Cartron G, Watier H, Golay J, et al. From the bench to the bedside: Ways to improve rituximab efficacy. Blood 2004 ; 104: 2635–2642.
13. 13 Parodi E, Nobili B, Perrotta S, et al. Rituximab (anti‐CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: Efficacy and safety of treatment. Int J Hematol 2006 ; 84: 48–53.
14. 14 Bennett C, Rogers Z, Kinamon D, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 2006 ; 107: 2639–2642.
15. 15 Faurschou M, Hasselbach H, Nielsen O. Sustained remission of platelet counts following monoclonal CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia. Eur J Haematol 2001 ; 66: 408–411.
16. 16 Stasi R, Stipa E, Forte V, et al. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood 2002 ; 99: 3872–3873.
17. 17 Quartier P, Brethon B, Phillip P, et al. Treatment of childhood autoimmune hemolytic anemia with rituximab. Lancet 2001 ; 358: 1511–1513.
18. 18 Tobinai K, Kobayashi Y, Narabayashi M, et al. Feasibility and pharcacokinetic study of a chimeric anti‐CD20 monoclonal antibody (IDEC‐C2B8, Rituximab) in relapsed B‐cell lymphoma. Ann Oncol 1998 ; 9: 527–534.
19. 19 Ng C, Bruno R, Combs D, et al. Population pharmacokinetics of rituximab (anti‐CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 2005 ; 45: 792–801.
20. 20 Edwards J, Leandro M, Cambridge G. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum Dis Clin North Am 2004 ; 30: 393–403.